1 results match your criteria: "2409 University Ave. Stop A 1930[Affiliation]"

Background And Objectives: Two oral calcitonin gene-related peptide (CGRP) antagonists, atogepant and rimegepant, were approved in 2021 for the preventive treatment of episodic migraine (EM), yet no formal cost-effectiveness analysis has been published. The objective of this study was to evaluate the cost-effectiveness of atogepant 60 mg and rimegepant 75 mg compared with placebo.

Methods: A decision tree model was constructed over a 1-year time horizon from a US societal perspective.

View Article and Find Full Text PDF